



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/942,075	08/28/2001	George Treacy	0148.1135-010	6161
21005	7590 - 05/18/2004		EXAMINER	
HAMILTON, BROOK, SMITH & REYNOLDS, P.C.			NOLAN, PATRICK J	
P.O. BOX 913	GINIA ROAD K 9133		ART UNIT	PAPER NUMBER
CONCORD, MA 01742-9133			1644	
			DATE MAILED: 05/18/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
	09/942,075	TREACY, GEORGE	
Office Action Summary	Examiner	Art Unit	
	Patrick J. Nolan	1644	
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address	
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply If NO period for reply is specified above, the maximum statutory period was a real period for reply within the set or extended period for reply will, by statute, any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be timed within the statutory minimum of thirty (30) days will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. O (35 U.S.C. § 133).	
Status			
1) ☐ Responsive to communication(s) filed on 23 Fe 2a) ☐ This action is FINAL. 2b) ☐ This 3) ☐ Since this application is in condition for allowar closed in accordance with the practice under E	action is non-final.  nce except for formal matters, pro		
Disposition of Claims			
4) ☐ Claim(s) 1-12 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1-12 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or	vn from consideration.		
Application Papers			
9) The specification is objected to by the Examine			
10) The drawing(s) filed on is/are: a) acce			
Applicant may not request that any objection to the one of the correction of the cor			
11) The oath or declaration is objected to by the Ex			
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list of	s have been received. s have been received in Application ity documents have been receive to (PCT Rule 17.2(a)).	on No d in this National Stage	
Attachment(s)  Notice of References Cited (PTO-892)  Notice of Draftsperson's Patent Drawing Review (PTO-948)  Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary ( Paper No(s)/Mail Dat 5) Notice of Informal Pa 6) Other:	te	

Art Unit: 1644

## Part III DETAILED ACTION

1. Claims 1-12 are pending.

## Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. § 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 2. Claim 5 stands rejected under 35 U.S.C. § 102(b) as being anticipated by Konno et al. (AV), of record, for reasons set forth in the Paper mailed 8-21-2003.

## Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. § 103 which forms the basis for all obviousness rejections set forth in this Office action:

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Subject matter developed by another person, which qualifies as prior art only under subsection (f) or (g) of section 102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

Application/Control Number: 09/942,075

Art Unit: 1644

3. Claim 1 stands rejected under 35 U.S.C. § 103 as being unpatentable over Konno et al. (AV) in view of Shah et al. (AY), all of record for reasons set forth in the Paper mailed 8-21-2003.

4. Claims 2 and 6 stand rejected under 35 U.S.C. 103(a) as being unpatentable over Konno et al., in view of Shah et al., as applied to claims 1 and 5 above, and further in view of U.S. Patent 5,698,195 (AA), all of record, for reasons set forth in the paper mailed 8-21-03.

Applicant's arguments filed 2-23-04 have been fully considered but are not found persuasive.

Applicant argues that Konno et al., is not applicable as prior art because the antibody was given prior to the LPS treatment and as such was not treatment.

However, there is no requirement in applicant's claim for when the antibody treatment must be given. It was taught by Konno et al., that LPS induces airway hyperresponsiveness in rats and that giving an anti-TNF-alpha antibody to rats that were subsequently given LPS treating those rats from the airway hyperresponsiveness that would have ensued.

5. Claims 1-12 stands rejected under 35 U.S.C. § 103 as being unpatentable over U.S. Patent 5,698,195 (AA), in view of Shah et al. (AY) and Lukacs et al. (AS), all of record, for reasons set forth in the paper mailed 8-21-03.

Applicant's arguments filed 2-23-04 have been fully considered but are not found persuasive.

Applicant argues there specification discloses many unexpected results with regards to the asthma treatment with the cA2 monoclonal antibody.

However, all of the claims are limited to the cA2 monoclonal antibody. Further the attorney's arguments with regards to what is unexpected and what is not is, are misplaced as they are not considered one of skill in the art. Please see MPEP 2145. A timely and properly filed 35 USC 1.132 declaration by one of skill in the art, or an art reference showing the results demonstrated in the application are unexpected would be useful.

Art Unit: 1644

6. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time

policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing

date of this final action.

7. The fax number for the organization where this application or proceeding is assigned is

703-872-9306.

8. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private

PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

9. Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Patrick Nolan whose telephone number is 571-272-0847.

If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Christina Chan, can be reached at 571-272-0841.

Patrick J. Nolan, Ph.D.

Primary Examiner, Group 1640

May 13, 2004